Zetidoline

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 341395

CAS#: 51940-78-4

Description: Zetidoline is a biochemicla.


Chemical Structure

img
Zetidoline
CAS# 51940-78-4

Theoretical Analysis

MedKoo Cat#: 341395
Name: Zetidoline
CAS#: 51940-78-4
Chemical Formula: C16H22ClN3O
Exact Mass: 307.1451
Molecular Weight: 307.822
Elemental Analysis: C, 62.43; H, 7.20; Cl, 11.52; N, 13.65; O, 5.20

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Zetidoline; MDL 308; MDL-308; MDL308.

IUPAC/Chemical Name: 1-(m-Chlorophenyl)-3-(2-(3,3-dimethyl-1-azetidinyl)ethyl)-2-imidazolidinone

InChi Key: AHDBQMJRRXVRDY-UHFFFAOYSA-N

InChi Code: InChI=1S/C16H22ClN3O/c1-16(2)11-18(12-16)6-7-19-8-9-20(15(19)21)14-5-3-4-13(17)10-14/h3-5,10H,6-9,11-12H2,1-2H3

SMILES Code: O=C1N(CCN2CC(C)(C)C2)CCN1C3=CC=CC(Cl)=C3

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

Preparing Stock Solutions

The following data is based on the product molecular weight 307.822 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Heidempergher F, Pillan A, Pinciroli V, Vaghi F, Arrigoni C, Bolis G, Caccia C, Dho L, McArthur R, Varasi M. Phenylimidazolidin-2-one derivatives as selective 5-HT3 receptor antagonists and refinement of the pharmacophore model for 5-HT3 receptor binding. J Med Chem. 1997 Oct 10;40(21):3369-80. PubMed PMID: 9341912.

2: Landi M, Dubini E, Zerilli LF. Quantitative determination of zetidoline, a new antipsychotic agent, in human blood plasma and saliva using capillary gas chromatograph-mass spectrometry. Boll Chim Farm. 1992 Sep;131(8):304-8. PubMed PMID: 1362884.

3: Bruhwyler J, Chleide E, Liégeois JF, Delarge J, Mercier M. Effects of specific dopaminergic agonists and antagonists in the open-field test. Pharmacol Biochem Behav. 1991 Jun;39(2):367-71. PubMed PMID: 1682946.

4: Tůma I, Zapletálek M, Krejsek J, Pidrman V. Some parameters of the immune system at schizophrenia therapy with chlorpromazine and zetidoline. Act Nerv Super (Praha). 1989 Dec;31(4):272-3. PubMed PMID: 2576921.

5: Korínková V. Clinical predictors of schizophrenic patient response to neuroleptics. Act Nerv Super (Praha). 1989 Jun;31(2):115-6. PubMed PMID: 2572131.

6: Collin S, Vercauteren DP, Vanderveken D, Evrard G, Durant F. Structural requirements of Na+-dependent antidopaminergic agents: Tropapride, Piquindone, Zetidoline, and Metoclopramide. Comparison with Na+-independent ligands. J Comput Aided Mol Des. 1989 Mar;3(1):39-53. PubMed PMID: 2715795.

7: Collin S, Evrard G, Vercauteren DP, Durant F, Carrupt PA, van de Waterbeemd H, Testa B. Stereoelectronic study of zetidoline, a dopamine D2 receptor antagonist. J Med Chem. 1989 Jan;32(1):38-42. PubMed PMID: 2521253.

8: Onali P, Olianas MC. Pharmacological and biochemical characterization of dopamine receptors mediating stimulation of a high affinity GTPase in rat striatum. Biochem Pharmacol. 1987 Sep 1;36(17):2839-45. PubMed PMID: 2820423.

9: Kilpatrick GJ, el Tayar N, Van de Waterbeemd H, Jenner P, Testa B, Marsden CD. The thermodynamics of agonist and antagonist binding to dopamine D-2 receptors. Mol Pharmacol. 1986 Sep;30(3):226-34. PubMed PMID: 2943980.

10: Assandri A, Galliani G, Zerilli L, Tuan G, Tarzia G, Barone D. Zetidoline metabolism by rat liver microsomes. Formation of metabolites with potential neuroleptic activity. Biochem Pharmacol. 1986 May 1;35(9):1459-67. PubMed PMID: 2871840.

11: Pugnetti P, Barone D, Peruzzi M, Restelli A. Zetidoline, a specific dopamine antagonist devoid of antiserotonergic activity in rodent brain. Pharmacol Res Commun. 1985 Dec;17(12):1141-51. PubMed PMID: 2869506.

12: Bateman DN. Studies on the pharmacological control of gastric emptying in man. Br J Clin Pharmacol. 1985 Oct;20(4):339-44. PubMed PMID: 3841005; PubMed Central PMCID: PMC1400888.

13: Barone D, Assandri A, Galliani G, Glässer A, Tarzia G. Characterization of [3H]zetidoline binding to rat striatal membranes. J Pharm Pharmacol. 1985 Mar;37(3):180-7. PubMed PMID: 2858565.

14: Mereu G, Fanni B, Collu M, Diena A, Glasser A. Zetidoline, a novel neuroleptic, activates nigral dopaminergic neurons in rats. Life Sci. 1985 Feb 4;36(5):459-64. PubMed PMID: 2857469.

15: Lobbezoo MW, Janszen FH, Tulp MT, Zwagemakers JM. Differential effects of metoclopramide and zetidoline on gastrointestinal motility. Eur J Pharmacol. 1985 Jan 22;108(2):105-12. PubMed PMID: 3979439.

16: Harris NC, Pinnock RD, Woodruff GN. Zetidoline blocks dopamine autoreceptors in the rat substantia nigra. Neuropharmacology. 1985 Jan;24(1):33-6. PubMed PMID: 2858831.

17: Assandri A, Perazzi A, Ferrari P, Martinelli E, Ripamonti A, Tarzia G, Tuan G. Metabolic fate of zetidoline, a new neuroleptic agent, in man. Naunyn Schmiedebergs Arch Pharmacol. 1985 Jan;328(3):341-7. PubMed PMID: 2858825.

18: Assandri A, Perazzi A, Fontanella L, Ferrari P, Ripamonti A, Tarzia G, Tuan G, Martinelli E. Metabolism of the neuroleptic agent zetidoline in the rat and the dog. Drug Metab Dispos. 1984 Sep-Oct;12(5):635-40. PubMed PMID: 6149917.

19: Silverstone T, Levine S, Freeman HL, Dubini A. Zetidoline, a new antipsychotic. First controlled trial in acute schizophrenia. Br J Psychiatry. 1984 Sep;145:294-9. PubMed PMID: 6148118.

20: Molcan J, Korínková V, Koníková M, Rakús A, Pribyl R. [Zetidoline in the treatment of schizophrenia--initial experiences]. Cesk Psychiatr. 1984 Jun;80(3):143-5. Slovak. PubMed PMID: 6148151.